Duke Street Bio Announces Appointment of Chief Medical Officer
Duke Street Bio is delighted to announce the strengthening of its executive leadership team with the appointment of Dónal Landers, MB BCh BAO, MBA, DPM, FFPM as Chief Medical Officer. Dr Landers is a highly experienced pharmaceutical physician with a proven track record of leading multiple molecules through early oncology clinical development. Dr Landers combines science, medicine with an entrepreneurial flair to drive translational and clinical drug development in oncology.
After obtaining his primary medical degree from Trinity College, Dublin, Dónal spent several years practicing hospital clinical medicine. He undertook an MBA at University College Dublin before transitioning to senior management at St. James’s Hospital. Dónal then co-founded his own health informatics company developing ‘patient-centric’ mobile technology solutions, enabling patients to collect and monitor their own health data.
After a number of years in various technology start-up companies, he joined PricewaterhouseCoopers as a specialist senior consultant and became sectoral lead for the healthcare and pharmaceutical group in Strategy Advisory. Dónal joined AstraZeneca (AZ) in 2010 as pharmaceutical physician in Early Clinical Development (ECD) where he was Senior Director Physician and led multiple targeted therapy clinical programs, including AZ’s first large multi-drug oncology Phase Ib ‘umbrella’ study in urothelial cancer (BISCAY). Most recently Dónal set up his own specialist consulting business, DeLondra Oncology, focusing on candidate selection to Phase II development, specialising in both early clinical and translational drug development in oncology.
Dónal was also co-founder and Strategic Director of the Digital Experimental Cancer Medicine Team based at Cancer Research UK Manchester Institute. This research team was setup to provide next generation patient cancer care using data-driven evidence to enable the transformation of clinical decision-making, the evolution of the role of the patient and the improvement of patient outcomes.
“The addition of Dr Landers comes at an exciting time for Duke Street Bio as we transition our best-in-class PARP1-selective and PARP7 inhibitor programs into the clinic. We are delighted to have him join the team.” said Alan Wise, CEO Duke Street Bio.